VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

November 14, 2026

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block- G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Outcome of Board Meeting held on November 14, 2026

Dear Sir / Madam

Pursuant to Regulation 33 and other applicable Regulations of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their Meeting held today i.e. Saturday, November 14, 2026, have inter alia, considered, approved and taken on record the following matters:

1. Approved the Unaudited Standalone Financial Results for the half-year ended September 30, 2026 along with Limited Review Report.
2. Approved the Unaudited Consolidated Financial Results for the half-year ended September 30, 2026 along with Limited Review Report.
3. Approved the Statement of Deviation regarding the utilisation of proceeds of the Preferential Issue, as certified by the Statutory Auditors of the Company.

Pursuant to Regulation 23(9) of SEBI (LODR) Regulations, 2015, Related Party Transactions on a consolidated basis are considered and approved for the half-year ended September 30, 2026.

The Unaudited Standalone and Consolidated Financial Results of the Company, along with the Limited Review Report for the half-year ended September 30, 2026 and Statement of the Deviation regarding the utilisation of proceeds of the Preferential Issue are enclosed herewith.

In furtherance to the Intimation filed by the Company dated September 28, 2026 the Trading Window for trading in the Securities of the Company, which was closed from October 1, 2026 until 48 hours after the declaration of the Standalone Financial Results, shall be opened after the expiry of forty-eight hours after declaration of the said Results.

The Meeting of the Board of Directors commenced at 3:00 P.M. and concluded at 5:10 P.M.

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:33:02 +05'30'

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF-YEAR ENDED SEPTEMBER 30, 2026

(Rs. in Lakhs)

	Particulars	Half - Year Ended			Year Ended	
		30-Sep 2026	31-Mar 2026	30-Sep 2025	31-Mar 2026	31-Mar 2025
		Unaudited	Audited	Unaudited	Audited	Audited
I	**Income**					
(a)	Revenue from Operations	3,260.00	3,259.90	966.40	4,226.30	1,480.99
(b)	Other Income	0.07	0.12	-	0.12	46.85
	Total Revenue	**3,260.07**	**3,260.02**	**966.40**	**4,226.42**	**1,527.84**
II	**Expenses**					
(a)	Cost of Materials Consumed	2,907.92	2,866.01	896.73	3,762.74	1,347.23
(b)	Purchase of Stock in Trade	-	-	-	-	-
(c)	Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	-	-	-	-	-
(d)	Employee Benefit Expenses	89.60	55.80	18.29	74.09	29.50
(e)	Finance Cost	0.01	0.11	6.77	6.88	84.51
(f)	Depreciation and Amortisation Expenses	20.35	21.03	7.45	28.48	10.44
(g)	Other Expenses	66.26	52.36	17.78	70.14	25.58
	Total Expenses	**3,084.14**	**2,995.31**	**947.02**	**3,942.33**	**1,497.26**
III	**Profit / (Loss) Before Exceptional Items and Tax**	**175.93**	**264.71**	**19.38**	**284.09**	**30.58**
	Exceptional Items	-	-	-	-	-
	Profit / (Loss) Before Tax	**175.93**	**264.71**	**19.38**	**284.09**	**30.58**
IV	**Tax Expense:**					
	(1) Current Tax	45.91	83.20	4.63	87.83	6.95
	(2) Deferred Tax	1.86	3.80	-0.42	3.38	1.28
	Profit / (Loss) for the Period from Continuing Operations	**128.16**	**177.71**	**15.17**	**192.88**	**22.35**
	Profit / (Loss) from Discontinued Operations	-	-	-	-	-
	Tax Expense of Discontinued Operations	-	-	-	-	-
	Profit / (Loss) from Discontinued Operations (After Tax)	-	-	-	-	-
V	**Profit / (Loss) for the Period**	**128.16**	**177.71**	**15.17**	**192.88**	**22.35**
	Other Comprehensive Income	-	-	-	-	-
	A (i) Items that will not be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-
	"Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period)"	-	-	-	-	-
VI	**Earnings Per Equity Share – Basic and Diluted**	**0.84**	**1.26**	**0.11**	**1.37**	**0.16**

Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667
Tel No: 040- 79618843 CIN: L24230TG2005PLC046689 GST: 36AACCV1433D1ZR
E-mail: cs@vilinbio.com Website: www.vilinbio.com

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

Notes to Accounts:

1. The above Unaudited Standalone Financial Results for the half-year ended September 30, 2026 as reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on November 14, 2026 and the Statutory Auditors of the Company have issued the Limited Review Report.
2. The Financial results have been prepared in accordance with applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and Accounting Principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
3. The Company operates in Single Segment hence the segment reporting is not applicable to the company.
4. Previous period figures have been re-classified/ re-grouped wherever considered necessary to confirm to the current period figures.

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY

Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:33:26 +05'30'

Madhusudhan Y Reddy
Managing Director
DIN: 02874260

Date: November 14, 2026
Place: Hyderabad

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

(Rs. in Lakhs)

	Particulars		As at 30-Sep-2026	As at 31-Mar-2026
			(Unaudited)	(Audited)
I	**EQUITY AND LIABILITIES**			
(A)	**Shareholder's Funds**			
(a)	Share Capital		1,525.00	1,525.00
(b)	Reserves and Surplus		1,440.40	1,312.24
(c)	Money received against Share Warrants		-	-
			2,965.40	**2,837.24**
(B)	**Non-Current Liabilities** Long-Term Borrowings Other Long-Term Liabilities Deferred Tax Liabilities (Net) Other Non-Current Liabilities			
(a)			-	-
(b)			14.67	12.81
(c)			-	-
(d)			-	-
			14.67	**12.81**
(C)	**Current Liabilities** Short Term Borrowings Trade Payables			
(a)			4.41	20.59
(b)	- Total Outstanding due to MSMEs		-	-
	- Total Outstanding dues other than MSMs		608.28	335.50
(c)	Other Current Liabilities		224.80	206.35
(d)	Short Term Provisions		126.58	81.73
			964.07	**644.17**
	Total Equity and Liabilities		**3,944.14**	**3,494.22**
II	**ASSETS**			
(A)	**Non-Current Assets**			
(a)	Property, Plant and Equipment and Intangible Assets			
	(i) Property, Plant and Equipment		305.34	286.51
	(ii) Capital work-in-progress		-	-
	(iii) Intangible Assets		-	-
(b)	Non - Current Investments		2.00	-
(c)	Deferred Tax Assets (Net)		-	-
(d)	Long Term Loans and Advances		-	-
(e)	Other Non-Current Assets		469.41	469.41
			776.75	**755.92**

Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843 **CIN: L24230TG2005PLC046689** **GST: 36AACCV1433D1ZR**

E-mail: cs@vilinbio.com **Website: www.vilinbio.com**

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

(B)	**Current Assets**			
(a)	Current investments		-	-
(b)	Inventories		1,049.22	721.53
(c)	Trade receivables		1,871.34	1,595.62
(d)	Cash and cash equivalents		21.52	146.99
(e)	Short-term loans and advances		57.07	43.29
(f)	Other current assets		168.24	230.87
			3,167.39	**2,738.30**
	Total Assets		**3,944.14**	**3,494.22**

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:33:47 +05'30'

Date: November 14, 2026
Place: Hyderabad

Madhusudhan Y Reddy
Managing Director
DIN: 02874260

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026		
Particulars	**As at 30-Sep-2026**	**As at 31-Mar-2026**
	Unaudited	**Audited**
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	175.93	284.09
Adjustment For	-	-
Depreciation	20.35	28.48
Foreign Exchange	-	-
Gain or Loss on Sale of Fixed Assets	-	-
Gain or Loss on Sale of Investment	-	-
Finance Cost	0.01	-
Dividend Income	-	-
Other adjustment of Non-Cash Item	-	-
Other adjustment to reconcile Profit	-	-
	20.36	28.48
Adjustment for Working Capital Change		
Adjustment for Increase/Decrease in Inventories	-327.69	-280.35
Adjustment for Increase/Decrease in Trade Receivables	-275.72	-740.11
Adjustment for Increase/Decrease in Other Current Assets	62.63	-84.39
Adjustment for Increase/Decrease in Other Non-Current Assets	-	-
Adjustment for Increase/Decrease in Short Term Borrowings	-	-
Adjustment for Increase/Decrease in Long Term Loans and Advances	-	-
Adjustment for Increase/Decrease in Short Term Loans and Advances	-13.78	531.29
Adjustment for Increase/Decrease in Trade Payables	272.78	191.61
Adjustment for Increase/Decrease in Other Current Liabilities	18.45	203.97
Adjustment for Provisions	-1.06	23.04
Total Adjustment for Working Capital (B)	**-264.39**	**-154.94**
Total Adjustment to reconcile Profit (A+B)	**-244.03**	**-126.46**
Net Cash Flow from (Used in) Operations	**-68.10**	**157.63**
Dividend Received	-	-
Interest Received	-	-
Interest Paid	-	-
Income Tax Paid / Refund	-	-87.83
Net Cash Flow from (used in) operation before Extra-ordinary Items	**-68.10**	**69.80**
Proceeds from Extra-ordinary Items	-	-

Payment for Extra-ordinary Items	-	-
Net Cash Flow from Operating Activities	**-68.10**	**69.80**
Cash Flows from Investing Activities		
Proceeds from Fixed Assets	-	-
Proceeds from Investment or Equity Instruments	-	-
Purchase of Fixed Assets	-39.18	-29.68
Purchase of Investments or Equity Instruments	-2.00	
Interest Received	-	-
Dividend Received	-	-
Cash Receipt from Sale of Interest in Joint Venture	-	-
Cash Payment to acquire Interest in Joint Venture	-	-
Cash Flow from losing Control of Subsidiaries	-	-
Cash Payment for acquiring Control of Subsidiaries	-	-
Proceeds from Government Grant	-	-
Other Inflow / Outflow of Cash	-	-
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	**-41.18**	**-29.68**
Proceeds from Extra Ordinary Items	-	-
Payment for Extra Ordinary Item	-	-
Net Cash Flow from (Used in) in Investing Activities	**-41.18**	**-29.68**
Cash Flows from Financial Activities		
Proceeds from Issue of Shares	-	130.00
Proceeds from Issuing shares for security premium	-	208.00
Proceeds from Issue of Debenture / Bonds / Notes	-	
Redemption of Preference Shares	-	-
Redemption of Debentures	-	-
Proceeds from other Equity Instruments	-	-
Proceeds from Borrowing		
Repayment of Borrowing	-16.18	-236.74
Dividend Paid	-	-
Interest Paid	-0.01	
Income Tax Paid / Refund	-	-
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	**-16.19**	**101.26**
Proceeds from Extra-ordinary Items	-	-
Payment for Extra-ordinary Items	-	-
Net Cash Flow from (Used in) in Financial Activities	**-16.19**	**101.26**
Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	**-125.47**	**141.38**
Effect of Exchange Rate change on Cash and Cash Equivalents	-	-

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

Net Increase (Decrease) in Cash and Cash Equivalents	**-125.47**	**141.38**
Cash and Cash Equivalents at beginning of period	146.99	5.61
Cash and Cash Equivalents at end of period	**21.52**	**146.99**

Date: November 14, 2026
Place: Hyderabad

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:34:09 +05'30'

Madhusudhan Y Reddy
Managing Director
DIN: 02874260

Independent Auditor's Limited Review Report on Half-Yearly Standalone Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors
Vilin Bio Med Limited

We have reviewed the accompanying Unaudited Standalone Financial Results ('the Statement') of Vilin Bio Med Limited ('the Company') for the half-year ended September 30, 2026, which comprise the Statement of Assets and Liabilities and the Statement of Cash Flows as at September 30, 2026, Statement of Profit and Loss, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations").

Management's Responsibility

The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Recognition and Measurement Principles laid down in Accounting Standard 25, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other Accounting Principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of Interim Financial information consists of making inquiries, primarily of persons responsible for Financial and Accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an Audit Opinion.



Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Recognition and Measurement Principles laid down in Accounting Standards specified under Section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other Accounting Principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG And CO
Chartered Accountants
FRN: 09655S



Girdhari Lal Toshniwal
Partner
M. No. 205140
UDIN: 26205140EALRKA3457

Date: 14/11/2026
Place: Hyderabad

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE HALF-YEAR ENDED SEPTEMBER 30, 2026

(Rs. in Lakhs)

	Particulars	Half - Year Ended			Year Ended	
		30-Sep 2026	31-Mar 2026	30-Sep 2025	31-Mar 2026	31-Mar 2025
		Unaudited	Audited	Unaudited	Audited	Audited
I	**Income**					
(a)	Revenue from Operations	3,260.00	3,259.90	966.40	4,226.30	1,480.99
(b)	Other Income	0.07	0.12	-	0.12	46.85
	Total Revenue	**3,260.07**	**3,260.02**	**966.40**	**4,226.41**	**1,527.84**
II	**Expenses**					
(a)	Cost of Materials Consumed	2,907.92	2,866.01	896.73	3,762.74	1,347.23
(b)	Purchase of Stock in Trade	-	-	-	-	-
(c)	Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	-	-	-	-	-
(d)	Employee Benefit Expenses	89.60	55.80	18.29	74.09	29.50
(e)	Finance Cost	0.02	0.11	6.77	6.88	84.51
(f)	Depreciation and Amortisation Expenses	20.35	21.03	7.45	28.48	10.44
(g)	Other Expenses	66.65	52.36	17.78	70.14	25.58
	Total Expenses	**3,084.54**	**2,995.31**	**947.02**	**3,942.33**	**1,497.26**
III	**Profit / (Loss) Before Exceptional Items and Tax**	**175.53**	**264.71**	**19.38**	**284.09**	**30.58**
	Exceptional Items	-	-	-	-	-
	Profit / (Loss) Before Tax	**175.53**	264.71	19.38	**284.09**	**30.58**
IV	**Tax Expense:**					
	(1) Current Tax	45.81	83.20	4.63	87.83	6.95
	(2) Deferred Tax	1.86	3.80	-0.42	3.38	1.28
	Profit / (Loss) for the Period from Continuing Operations	**127.86**	**177.71**	**15.17**	**192.88**	**22.35**
	Profit / (Loss) from Discontinued Operations	-	-	-	-	-
	Tax Expense of Discontinued Operations	-	-	-	-	-
	Profit / (Loss) from Discontinued Operations (After Tax)	-	-	-	-	-
V	**Profit / (Loss) for the Period**	**127.86**	**177.71**	**15.17**	**192.88**	**22.35**
	Other Comprehensive Income	-	-	-	-	-
	A (i) Items that will not be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-
	"Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-
VI	**Earnings Per Equity Share - Basic and Diluted**	**0.84**	**1.26**	**0.11**	**1.37**	**0.16**

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

Notes to Accounts:

1. The above Unaudited Consolidated Financial Results for the half-year ended September 30, 2026 as reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on November 14, 2026 and the Statutory Auditors of the Company have issued the Limited Review Report.
2. The Financial results have been prepared in accordance with applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and Accounting Principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
3. During the period the company has incorporated two subsidiaries namely M/s. Axia Pharma Private Limited incorporated on July 16, 2026 and M/s. Vilo Speciality Pharma Private Limited incorporated on July 23, 2026. The consolidated financial statements have been presented for half year ended September 30, 2026 while the remaining financial results pertains solely to Vilin Bio Med Limited.
4. The Company operates in Single Segment hence the segment reporting is not applicable to the company.
5. Previous period figures have been re-classified/ re-grouped wherever considered necessary to confirm to the current period figures.

Date: November 14, 2026
Place: Hyderabad

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY

Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:34:37 +05'30'

Madhusudhan Y Reddy
Managing Director
DIN: 02874260

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

(Rs. in Lakhs)

	Particulars		As at 30-Sep-2026	As at 31-Mar-2026
			(Unaudited)	(Audited)
I	**EQUITY AND LIABILITIES**			
(A)	**Shareholder's Funds**			
(a)	Share Capital		1,525.00	1,525.00
(b)	Reserves and Surplus		1,440.10	1,312.24
(c)	Money received against Share Warrants		-	-
			2,965.10	**2,837.24**
(B)	**Non-Current Liabilities**			
(a)	Long-Term Borrowings		-	-
(b)	Other Long-Term Liabilities		-	-
(c)	Deferred Tax Liabilities (Net)		14.67	12.81
(d)	Other Non-Current Liabilities		-	-
(C)	**Current Liabilities**			
(a)	Short Term Borrowings		4.41	20.59
(b)	Trade Payables			
	- Total Outstanding due to MSMEs		-	-
	- Total Outstanding dues other than MSMs		607.94	335.50
(c)	Other Current Liabilities		224.80	206.35
(d)	Short Term Provisions		126.48	81.73
			963.63	**644.17**
	Total Equity and Liabilities		**3,943.40**	**3,494.22**
II	**ASSETS**			
(A)	**Non-Current Assets**			
(a)	Property, Plant and Equipment and Intangible Assets			
	(i) Property, Plant and Equipment		305.34	286.51
	(ii) Capital work-in-progress			
	(iii) Intangible Assets			
(b)	Non - Current Investments			
(c)	Deferred Tax Assets (Net)			
(d)	Long Term Loans and Advances			
(e)	Other Non-Current Assets		469.41	469.41

			774.75	**755.92**
(B)	**Current Assets**			
(a)	Current investments		-	-
(b)	Inventories		1,049.22	721.53
(c)	Trade Receivables		1,871.34	1,595.62
(d)	Cash and Cash Equivalents		22.78	146.99
(e)	Short Term Loans and Advances		57.07	43.29
(f)	Other Current Assets		168.24	230.87
			3,168.65	**2,738.30**
	Total Assets		**3,943.40**	**3,494.22**

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY

Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:34:58 +05'30'

Madhusudhan Y Reddy
Managing Director
DIN: 02874260

Date: November 14, 2026
Place: Hyderabad

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026		
Particulars	**As at 30-Sep-2026**	**As at 31-Mar-2026**
	Unaudited	**Audited**
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	175.53	284.09
Adjustment For	-	-
Depreciation	20.35	28.48
Foreign Exchange	-	-
Gain or Loss on Sale of Fixed Assets	-	-
Gain or Loss on Sale of Investment	-	-
Finance Cost	0.02	-
Dividend Income	-	-
Other adjustment of Non-Cash Item	-	-
Other adjustment to reconcile Profit	-	-
	20.37	**28.48**
Adjustment for Working Capital Change		
Adjustment for Increase/Decrease in Inventories	-327.69	-280.35
Adjustment for Increase/Decrease in Trade Receivables	-275.72	-740.11
Adjustment for Increase/Decrease in Other Current Assets	62.63	-84.39
Adjustment for Increase/Decrease in Other Non-Current Assets	-	-
Adjustment for Increase/Decrease in Short Term Borrowings	-	-
Adjustment for Increase/Decrease in Long Term Loans and Advances	-	-
Adjustment for Increase/Decrease in Short Term Loans and Advances	-13.78	531.29
Adjustment for Increase/Decrease in Trade Payables	272.44	191.61
Adjustment for Increase/Decrease in Other Current Liabilities	18.45	203.97
Adjustment for Provisions	-1.06	23.04
Total Adjustment for Working Capital (B)	**-264.73**	**-154.94**
Total Adjustment to reconcile Profit (A+B)	**-244.36**	**-126.46**
Net Cash Flow from (Used in) Operations	**-68.83**	**157.63**
Dividend Received	-	-
Interest Received	-	-
Interest Paid	-	-

Income Tax Paid / Refund	-	-87.83
Net Cash Flow from (used in) operation before Extra-ordinary Items	**-68.83**	**69.80**
Proceeds from Extra-ordinary Items	-	-
Payment for Extra-ordinary Items	-	-
Net Cash Flow from Operating Activities	**-68.83**	**69.80**
Cash Flows from Investing Activities		
Proceeds from Fixed Assets	-	-
Proceeds from Investment or Equity Instruments	-	-
Purchase of Fixed Assets	-39.18	-29.68
Purchase of Investments or Equity Instruments	-	
Interest Received	-	-
Dividend Received	-	-
Cash Receipt from Sale of Interest in Joint Venture	-	-
Cash Payment to acquire Interest in Joint Venture	-	-
Cash Flow from losing Control of Subsidiaries	-	-
Cash Payment for acquiring Control of Subsidiaries	-	-
Proceeds from Government Grant	-	-
Other Inflow / Outflow of Cash	-	-
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	**-39.18**	**-29.68**
Proceeds from Extra Ordinary Items	-	-
Payment for Extra Ordinary Item	-	-
Net Cash Flow from (Used in) in Investing Activities	**-39.18**	**-29.68**
Cash Flows from Financial Activities		
Proceeds from Issue of Shares	-	130.00
Proceeds from Issuing shares for security premium	-	208.00
Proceeds from Issue of Debenture / Bonds / Notes	-	
Redemption of Preference Shares	-	-
Redemption of Debentures	-	-
Proceeds from other Equity Instruments	-	-
Proceeds from Borrowing		
Repayment of Borrowing	-16.18	-236.74
Dividend Paid	-	-
Interest Paid	-0.02	
Income Tax Paid / Refund	-	-
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	**-16.20**	**101.26**
Proceeds from Extra-ordinary Items	-	-
Payment for Extra-ordinary Items	-	-
Net Cash Flow from (Used in) in Financial Activities	**-16.20**	**101.26**

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	**-124.21**	**141.38**
Effect of Exchange Rate change on Cash and Cash Equivalents	-	-
Net Increase (Decrease) in Cash and Cash Equivalents	**-124.21**	**141.38**
Cash and Cash Equivalents at beginning of period	146.99	5.61
Cash and Cash Equivalents at end of period	**22.78**	**146.99**

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY

Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:35:19 +05'30'

Madhusudhan Y Reddy
Managing Director
DIN: 02874260

Date: November 14, 2026
Place: Hyderabad

Independent Auditor's Limited Review Report on Half-Yearly Consolidated Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors
Vilin Bio Med Limited

We have reviewed the accompanying Unaudited Consolidated Financial Results ('the Statement') of Vilin Bio Med Limited ('the Company') for the half-year ended September 30, 2026, which comprise the Statement of Assets and Liabilities and the Statement of Cash Flows as at September 30, 2026, Statement of Profit and Loss, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations").

Management's Responsibility

The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Recognition and Measurement Principles laid down in Accounting Standard 25, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other Accounting Principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of Interim Financial information consists of making inquiries, primarily of persons responsible for Financial and Accounting matters, and applying analytical and other review procedures. A Review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143 (10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an Audit Opinion.

The Statement includes the results of the Subsidiaries listed below:

1. VILO SPECIALITY PHARMA PRIVATE LIMITED
2. AXIA PHARMA PRIVATE LIMITED

PPKG & CO. HYDERABAD Chartered Accountants

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the Recognition and Measurement Principles laid down in Accounting Standards specified under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereafter and other Accounting Principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

These Consolidated Financials include the Financials of M/s Axia Pharma Private Limited in which M/s Vilin Bio Med Limited, the Holding Company, holds 100% stake. M/s Axia Pharma Private Limited has been recently incorporated and presently has not commenced any business activity.

These Consolidated Financials include the financials of M/s Vilo Speciality Pharma Private Limited M/s Vilin Bio Med Limited, the Holding Company, holds 100% stake. M/s Vilo Speciality Pharma Private Limited has been recently incorporated and presently has not commenced any business activity.

For PPKG And CO
Chartered Accountants
FRN: 09655S

PPKG & CO. HYDERABAD Chartered Accountants

Girdhari Lal Toshniwal
Partner
M. No. 205140
UDIN: 26205140HCGZUE8692

Date: 14/11/2026
Place: Hyderabad

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

November 14, 2026

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block- G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Statement of Deviation and Variation for Utilization of Funds Raised through Preferential Issue

Dear Sir / Madam

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that there have been no Deviation (s) or Variation (s) in the utilisation of Proceeds raised through Preferential Issue; and proceeds are utilised as per the Objects stated in the Offer Document.

We enclose herewith the Statement of Deviation or Variation for half-year ended 30 September, 2026 as reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective Meeting held on Saturday, November 14, 2026.

Kindly take the same on record.

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:35:47 +05'30'

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260

Name of Listed Entity	Vilin Bio Med Limited
Mode of Fund Raising	Preferential Issue
Date of Raising Funds	March 4, 2026
Amount Raised	Rs.338.00 Lakhs
Report filed for half-year ended	September 30, 2026
Monitoring Agency	NA
Monitoring Agency Name	NA
Is there a Deviation / Variation in use of Funds raised ?	No
Whether any approval is required to vary the Objects of the Issue stated in the Prospectus / Offer Document?	No
If yes, details of the approval so required?	NA
Date of Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	Nil
Comments of the Auditors, if any	Nil
Objects for which Funds have been raised and wherethere has been a deviation, in the following table	No Deviation

PPKG & CO. HYDERABAD Chartered Accountants

Original Object	Modified Object	Original Allocation (Rs. in Lakhs)	Modified Allocation	Funds Utilised (Rs. in Lakhs)	Balance Amount (Rs. in Lakhs)	Amount of Deviation / Variation for the applicable Object
Working Capital	NA	327.00	NA	327.00	0.00	NA
Issue Expenses	NA	11.00	NA	11.00	0.00	NA
Total		338.00		338.00	0.00	

Deviation could mean:

(a) Deviation in the Objects or purposes for which the Funds have been raised
(b) Deviation in the amount of Funds actually utilised as against what was originally disclosed.
(c) Change in terms of Contract referred to the Fund-raising document i.e., Prospectus / Letter of Offer, etc.

For PPKG & Co
Chartered Accountants
FRN: 009655S

PPKG & CO. HYDERABAD Chartered Accountants

Girdhari lal Toshinwal
Partner
M. No. 205140
UDIN: 26205140TVFCMT8860

Date : November 14, 2026
Place: Hyderabad